Nanobiotix (NBTX) EBIAT (2020 - 2025)
Nanobiotix has reported EBIAT over the past 6 years, most recently at -$27.9 million for Q4 2025.
- For Q4 2025, EBIAT rose 61.69% year-over-year to -$27.9 million; the TTM value through Dec 2025 reached -$130.3 million, up 23.18%, while the annual FY2025 figure was -$27.9 million, 61.69% up from the prior year.
- EBIAT for Q4 2025 was -$27.9 million at Nanobiotix, down from -$6.1 million in the prior quarter.
- Over five years, EBIAT peaked at -$6.1 million in Q2 2025 and troughed at -$72.8 million in Q4 2024.
- A 5-year average of -$38.0 million and a median of -$33.6 million in 2021 define the central range for EBIAT.
- Biggest five-year swings in EBIAT: tumbled 70.45% in 2024 and later skyrocketed 74.13% in 2025.
- Year by year, EBIAT stood at -$53.8 million in 2021, then decreased by 8.23% to -$58.2 million in 2022, then increased by 26.6% to -$42.7 million in 2023, then tumbled by 70.45% to -$72.8 million in 2024, then soared by 61.69% to -$27.9 million in 2025.
- Business Quant data shows EBIAT for NBTX at -$27.9 million in Q4 2025, -$6.1 million in Q2 2025, and -$72.8 million in Q4 2024.